secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0000950170-24-134064
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts IND for Gemini Phase 1b CKD study; REVB raises ~$4.1M from warrant exercises
--------------------------------------------------------------------------------

- FDA accepted IND for Gemini (trained immunity) for Phase 1b study in up to 40 CKD patients; primary endpoint safety/tolerability.
- Existing Class E warrants exercised at $1.00/share for ~$4.1M gross proceeds; new Class F and G warrants issued as inducement.
- Proceeds to fund clinical trials for GEM-AKI, GEM-CKD, GEM-PSI and working capital.
- New Class F warrants (2yr, $1.00) and Class G warrants (5yr, $1.00) subject to stockholder approval; include cashless exercise provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024134064/0000950170-24-134064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024134064/revb-20241203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer